KEYNOTE-062 Highlights Role of Pembrolizumab in Gastric/GEJ Cancer Subtypes
David H. Ilson, MD, PhD, discusses the current role of pembrolizumab in patients with gastric cancer or gastroesophageal junction adenocarcinoma based on the results from the KEYNOTE-062 trial.
David H. Ilson, MD, PhD, an attending physician and professor of medicine at Memorial Sloan Kettering Cancer Center, discusses the current role of pembrolizumab (Keytruda) in patients with gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma based on the results of the KEYNOTE-062 trial.
Although PD-L1 is thought to be somewhat of a predictive biomarker in patients with microsatellite stable disease, the response rates were higher in this subset of patients with a combined positive score of 10 or higher, says Ilson. The response rates were even slightly higher in those patients who received pembrolizumab and chemotherapy, but there was no improvement in survival compared with chemotherapy alone.
The problem with upfront pembrolizumab is that a vast majority of the patients will progress and cross over to chemotherapy early on. However, Ilson argues that this is not a fair comparison because virtually all patients that receive pembrolizumab initially will also get chemotherapy within a few months.
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
